{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:48Z","timestamp":1788013128389,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12185-022-03499-2","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T04:31:55Z","timestamp":1670905915000},"page":"769-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of Epstein\u2013Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma"],"prefix":"10.1007","volume":"117","author":[{"given":"Mina","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Jona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Imadome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"3","key":"3499_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","volume":"4","author":"Y Okuno","year":"2019","unstructured":"Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4(3):404\u201313.","journal-title":"Nat Microbiol"},{"issue":"9","key":"3499_CR2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdp064","volume":"20","author":"JI Cohen","year":"2009","unstructured":"Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8\u20139 September 2008. Ann Oncol. 2009;20(9):1472\u201382.","journal-title":"Ann Oncol"},{"issue":"1","key":"3499_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/JVI.01512-10","volume":"85","author":"SD Ma","year":"2011","unstructured":"Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol. 2011;85(1):165\u201377.","journal-title":"J Virol"},{"issue":"19","key":"3499_CR4","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-15-2242","volume":"22","author":"RJ Jones","year":"2016","unstructured":"Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, et al. Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and Ikaros expression. Clin Cancer Res. 2016;22(19):4901\u201312.","journal-title":"Clin Cancer Res"},{"issue":"6168","key":"3499_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2013","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The Myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2013;343(6168):305\u20139.","journal-title":"Science"},{"issue":"9","key":"3499_CR6","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1128\/JVI.03706-13","volume":"88","author":"T Iempridee","year":"2014","unstructured":"Iempridee T, Reusch JA, Riching A, Johannsen EC, Dovat S, Kenney SC, et al. Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells. J Virol. 2014;88(9):4811\u201327.","journal-title":"J Virol"},{"issue":"2","key":"3499_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"3499_CR8","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728\u201338.","journal-title":"Blood"},{"issue":"11","key":"3499_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C M\u00fcnz","year":"2019","unstructured":"M\u00fcnz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019;17(11):691\u2013700.","journal-title":"Nat Rev Microbiol"},{"issue":"18","key":"3499_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","volume":"132","author":"Y Natkunam","year":"2018","unstructured":"Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JKC, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132(18):1871\u20138.","journal-title":"Blood"},{"issue":"1","key":"3499_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/PAS.0000000000000954","volume":"42","author":"S Pina-Oviedo","year":"2018","unstructured":"Pina-Oviedo S, Miranda RN, Jeffrey L, Medeiros M. Cancer therapy-associated lymphoproliferative disorders: an under-recognized type of immunodeficiency-associated lymphoproliferative disorder. Am J Surg Pathol. 2018;42(1):116\u201329.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"3499_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/his.13464","volume":"72","author":"T Daroontum","year":"2018","unstructured":"Daroontum T, Kohno K, Eladl AE, Satou A, Sakakibara A, Matsukage S, et al. Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan. Histopathology. 2018;72(7):1115\u201327.","journal-title":"Histopathology"},{"issue":"9","key":"3499_CR13","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","volume":"118","author":"E Kneppers","year":"2011","unstructured":"Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413\u20139.","journal-title":"Blood"},{"key":"3499_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0071-x","author":"K Suzuki","year":"2018","unstructured":"Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, et al. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018. https:\/\/doi.org\/10.1038\/s41408-018-0071-x.","journal-title":"Blood Cancer J"},{"issue":"9","key":"3499_CR15","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2019-215361","volume":"78","author":"NR Jog","year":"2019","unstructured":"Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019;78(9):1235\u201341.","journal-title":"Ann Rheum Dis"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03499-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:26:56Z","timestamp":1744208816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03499-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3499"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03499-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.K. received research funding from Pfizer, Otsuka Pharmaceutical, Chugai Pharmaceutical, Astellas, Kyowa Kirin, Takeda Pharmaceutical, Teijin, Eisai, Sumitomo Dainippon Pharma, Nippon Shinyaku, AbbVie, Daiichi Sankyo and Ono Pharmaceutical; advisory fees from Kyowa Kirin, Celgene, Chugai Pharmaceutical and MSD; and lecture fees from MSD, Astellas, Otsuka Pharmaceutical, Ono Pharmaceutical, Celgene, Daiichi Sankyo, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Chugai Pharmaceutical, Janssen Pharmaceutical, Kyowa Kirin, AbbVie, Pfizer, AstraZeneca, Bristol-Myers Squibb, Amgen, Sanwa Kagaku, Sanofi, SymBio Pharmaceutical and Nippon Shinyaku. M.J. reports lecture fees from Bristol-Myers Squibb K.K.; and lecture fees from Novartis Pharma K.K. None of these are related to the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}